Core Viewpoint - Altisource Portfolio Solutions S.A. has announced the approval and upcoming trading of two types of warrants on the Nasdaq Global Select Market, which are expected to provide investment opportunities for stakeholders [1]. Group 1: Warrants Overview - The company has distributed two types of warrants: Cash Exercise Stakeholder Warrants and Net Settle Stakeholder Warrants, which will trade under the tickers "ASPSZ" and "ASPSW" respectively [1]. - Each warrant allows the holder to purchase 1.625 shares of common stock at an exercise price of $1.95 per warrant, initially equivalent to $1.20 per share [2]. - The Cash Exercise Stakeholder Warrants will expire on April 2, 2029, while the Net Settle Stakeholder Warrants will expire on April 30, 2032 [3]. Group 2: Exercise Conditions - Warrants can be exercised starting from July 2, 2025, or the first date when the volume-weighted average price (VWAP) of the common stock meets or exceeds the implied per share exercise price of $1.20 for fifteen consecutive trading days [2]. - The company will not issue fractional shares upon exercise; any fractional shares will be rounded down to the nearest whole number [2]. Group 3: Company Background - Altisource Portfolio Solutions S.A. is a leading integrated service provider and marketplace for the real estate and mortgage industries, focusing on operational excellence and innovative services [7].

Reference is made to the announcement by IDEX Biometrics ASA (the "Company") on 12 December 2024 regarding the listing of Warrants A and Warrants B on Oslo Stock Exchange. Warrants B were exercisable between 31 March 2025 and 11 April 2025, and all Warrants B not exercised within such time lapsed without compensation to the holder. A total of 36,767 Warrants B were exercised, resulting in an aggregate subscription for 36,767 new shares (the "New Shares") in the Company, each Warrant B having an exercise pri ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “2023 Warrants”). The 2023 Warrants were issued in connection with the clos ...

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]

Core Points - Opus One Gold Corporation closed a second and final tranche of its non-brokered private placement of flow-through shares and units, raising aggregate gross proceeds of $578,450.25 on April 25, 2025 [1] - The total issuance included 5,353,850 flow-through shares at $0.065 each and 4,190,000 units at $0.055 each, with each unit consisting of one common share and one warrant [2] - The overall gross proceeds from both tranches amounted to $1,545,700.30, with funds allocated for exploration on mineral properties and general working capital [3] Financial Details - The company issued a total of 20,234,620 flow-through shares and 4,190,000 units across both tranches [3] - Cash finders fees amounted to $26,150, and a total of 369,230 compensation warrants were issued, each exercisable at $0.10 for 24 months [5] - Previous private placement details included 995,636 finders' warrants and $101,460 in cash finders' fees [6] Regulatory and Compliance - The offering was conducted under the "accredited investor" exemption in Canada, with a four-month hold period applicable to the securities issued [4] - Closing of the offering is subject to approval from the TSX Venture Exchange and customary closing conditions [5] Company Overview - Opus One Gold Corporation focuses on discovering high-quality gold and base metals deposits in the Abitibi Greenstone Belt, a prolific mining area [8]

Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 29 April 2025 (“Vast” or the “Company”) Exercise of Warrants Vast Resources plc, the AIM quoted mining company, announces that it has received notice to exercise warrants over a total of 195,000,000 new ordinary shares of 0.1 pence each in the Company ("Warrant Shares") at an exercise price of 0.4p per Warrant Share, raising £780,000 for the Company. Application has been made to the London Stock Exchange for 195,000,000 new Ordinary Shares to b ...

DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share option scheme. All thes ...

Core Viewpoint - BioPorto A/S has issued 1,700,000 warrants to its Board of Directors as part of their remuneration, with each warrant allowing the purchase of one share at an exercise price of DKK 1.50, reflecting the current closing price on Nasdaq Copenhagen [1][2]. Summary by Sections Warrants Issuance - The issuance of warrants was approved during the annual general meeting on April 11, 2025, and is part of the company's compensation strategy for its Board members [1]. - The warrants will vest in equal tranches quarterly over a two-year period, with the first tranche becoming available at the start of the first calendar quarter following the grant date [3]. Terms and Conditions - The warrants are governed by the company's incentive warrant program and include provisions for claw-back in cases of erroneous financial information and accelerated vesting in the event of a takeover or business combination [4]. - The theoretical market value of the newly issued warrants is calculated to be DKK 1,843,580, based on the Black-Scholes formula, with an interest rate of 2.37% and historical volatility of 63.82% over 120 months [5]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable biomarkers to enhance patient management and improve clinical outcomes [7]. - The company's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of Acute Kidney Injury (AKI), enabling faster identification and intervention for at-risk patients [8]. - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [9].

M-tron Industries, Inc. (NYSE:MPTI) Q4 2024 Earnings Conference Call February 27, 2025 10:00 AM ET Company Participants Linda Biles - EVP of Finance and CAO Cameron Pforr - Interim CEO Conference Call Participants Anja Soderstrom - Sidoti & Company James Tivy - Operator Thank you for standing by. My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome everyone to the M-tron Investor Update. [Operator Instructions] I would now like to turn the call over to Mr ...